Skip to content
Cultural Foundation
Author:
Cloudbreak Pharma, Inc.
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
June 4, 2026
Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum
May 12, 2026
Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026
April 22, 2026
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases
April 9, 2026